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Abstract
Background: Avian influenza A (H5N1) virus is one of the most important public health concerns worldwide. The
antiviral activity of native and esterified whey proteins fractions (a- lactalbumin, b- lactoglobulin, and lactoferrin)
was evaluated against A/chicken/Egypt/086Q-NLQP/2008 HPAI (H5N1) strain of clade 2.2.1 (for multiplicity of
infection (1 MOI) after 72 h of incubation at 37°C in the presence of 5% CO2) using MDCK cell lines.
Result: Both the native and esterified lactoferrin seem to be the most active antiviral protein among the tested
samples, followed by b- lactoglobulin. a-Lactalbumin had less antiviral activity even after esterification.
Conclusion: Esterification of whey proteins fractions especially lactoferrin and b-lactoglobulin enhanced their
antiviral activity against H5N1 in a concentration dependent manner.
Background
Avian influenza A (H5N1) virus is one of the most
important public health concerns worldwide. It has been
detected and identified in South East Asia since 2003. In
2005, the virus was already spread to many countries in
Europe, Asia and Africa [1]. Later it interrupted interna-
tional travel and negatively affected the world economy
especially tourism.
In December 2005, the first case of H5N1 in Egypt
was detected in a migrating bird in Damietta Governor-
ate. In mid-February 2006, H5N1 infection was reported
in Egypt among domestic poultry in more than 15 gov-
ernorates, resulting in seve r el o s s e sf o rt h ep o u l t r y
industry. In March 2006, the first human case of H5N1
in Egypt was detected [2]. Egypt had the highest number
of confirmed human avian influenza cases outside Asia.
As of 4 March 2010, 104 human cases, including 30
fatalities, had been recorded in Egypt [3,4].
Whey proteins have been reported to have numerous
therapeutic applications including effects on bone (sti-
mulate proliferation and differentiation of osteoblastic
cells as well as suppress bone resorption and increase
femoral bone strength), muscles (enhancing muscle
hypertrophy and strength due to its leucine content),
blood (lower blood pressure and reduce the risk of
hypertension), brain (increase brain serotonin levels),
immune system (stimulate immunity and improving
immune function), cancer (increase NK cell function
and glutathione levels), wound healing (essential for
post-surgical wound healing and protein depletion
delays healing time), and aging (antiaging agent due to
the whey content of glutathione/antioxidant compo-
nent). Furthermore, they act as antioxidant, antihyper-
tensive, antiviral, antimicrobial, chelating agent and
prevent cardiovascular diseases and osteoporosis [5,6].
The biological value of whey proteins has also been
reviewed for their antimicrobial and antiviral functions
[7-11].
Modification of whey proteins to enhance or alter
their biological and functional properties may increase
its applications. Whey proteins modification can be
accomplished by chemical, enzymatic, or physical tech-
niques [12]. Additional negative charges on b-lactoglo-
bulin (BLG), a-lactalbumin (ALA) and human serum
albumin (HSA) endowed them a significant antiviral
activities against human immunedeficiency viruses—
HIV-1 and HIV-2 [13-17]. BLG modified with 3-hydro-
xyphthaloylacid (3HP) inhibited the infection with HIV-
1, Herpes simplex virus types 1 and 2 and human cyto-
megalovirus [18,19]. In addition, many studies reported
that increasing the net positive charge on whey proteins
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any medium, provided the original work is properly cited.led to enhancement of its antiviral activity. Esterified
whey proteins showed antiviral activity against polio-
virus type-1, Coxsackie virus B6, human cytomegalo-
virus, Herpes simplex virus type 1 and human influenza
virus A subtype H3N2 & subtype H1N1 [20-24].
Therefore, it was thought worthwhile to test the effi-
cacy of native and modified whey proteins fractions
against influenza virus subtype H5N1which may be use-
ful for the prophylaxis and treatment of influenza
viruses and at the same time can be a potential and low
cost alternative candidate for an anti-influenza agent.
Materials and methods
Materials
The HPAI H5N1 A/chicken/Egypt/086Q-NLQP/2008
(referred to as EGYvar/H5N1) virus (GenBank accession
number: EU496398.1) was isolated from an H5 vacci-
nated commercial chicken farm in 2008 during the rou-
tine national surveillance conducted by the National
Laboratory for Veterinary Quality Control on Poultry
Production (NLQP), Giza, Egypt. The virus has been
titrated using Hemagglutination test (HA) 256 HAU.
The tissue culture lethal dose 100% (TCLD100%), tissue
culture infective dose 50% (TCID50%) and Embryonated
egg infected dose 50% (EID50%) were calculated using
Read and Minch (10
6,1 0
8.26,1 0
8.64/ml respectively) in
Specific Pathogen Free Embryonated Chicken Egg (SPF
ECE) and Madin-Darby Canine Kidney Cells (MDCK) as
described in WHO manual [25]. SPF ECE was obtained
from Qom Oshime SPF farm Egypt, and MDCK was
obtained from NAMRU3 unit, Egypt.
a-Lactalbumin (97.46% protein) and b-lactoglobulin
(97.8% protein) were kindly obtained from Davisco Food
International (USA) while lactoferrin (95% protein) was
kindly obtained from Armor Proteins (France). All other
chemicals used in this study were of analytical grade.
Methods
1-Protein Esterification
The procedure of [26] was used for esterification of
whey proteins fractions.
2-Esterification extent
The extent of esterification of proteins was quantified by
the colour reaction with hydroxylamine hydrochloride as
described by [27].
3- The antiviral activity of native and esterified whey
protein
The antiviral activity of native and esterified whey pro-
teins: a-lactalbumin (ALA), b-lactoglobulin (BLG) and
lactoferrin (LF) was assayed against Egyptian highly
pathogenic avian virus A/chicken/Egypt/086Q-NLQP/
2008 HPAI (H5N1) strain of clade 2.2.1 at concentra-
t i o n so f1 . 0 0M O I( m u l t i p l i c i t yo fi n f e c t i o n )p e rc e l l
according to [22].
4- Statistical analysis
All experiments were performed in triplicates and the
results were expressed by the mean plus the standard
deviation.
Results
Extent of esterification
The whey proteins fractions ALA, BLG and LF were
modified to the extent of 68%, 100% and 100% respec-
tively which indicates less esterification susceptibility of
ALA as compared to both BLG and LF. The observed
extents of such esterification are in accordance with
[26].
Antiviral activity of whey proteins fractions
Data shown in Figure 1 demonstrate the antiviral effect
of native and esterified whey proteins fractions against
H5N1 propagated in MDCK cells at 100% (1.00 MOI)
level of viral infection. Native proteins have exhibited
different levels of inhibitory effects against the virus. It
ranged from 21.62 ± 2.1 to 26.40 ± 1.5% for ALA, from
32.87 ± 2.3 to 42.43 ± 1.3% for BLG and from 34.98 ±
5.5 to 70.92 ± 3.2% for LF in response to protein con-
centration increasing from 20 to 80 μg/ml. The differ-
ence in viral inhibitory effect of the three native
proteins may be due to the difference in their structural
nature. Native lactoferrin seems to be the most active
antiviral protein among the tested samples, probably
due to its more basic nature that enables its interference
and interaction with the viral constituents affecting viral
replication and activity. Esterification of whey proteins
fractions has further enhanced their antiviral activity
against H5N1 in a concentration dependent manner.
Met-ALA exhibited antiviral effect ranging from 54.84 ±
0.1 to 79.57 ± 2.0%, Met-BLG from 64.88 ± 1.9 to 99.05
± 0.4% and Met-LF from 69.28 ± 1.8 to 99.42 ± 0.6% in
response to protein concentration going from 20 to
80 μg/ml. Met-ALA was the lowest active as antiviral
protein even after esterification while both Met-BLG
and Met-LF reached maximum antiviral influence when
the protein concentration was increased to 80 μg/ml.
This may confirm that esterification is a potent tool
which introduces this antiviral activity into native pro-
teins. It may also show that the original differences
between BLG and lactoferrin disappeared completely
after esterification.
The antiviral activity of the tested proteins may be due
to its interaction with influenza nuclear proteins (PB1,
PB2, PA and NP), which catalyze the transcription of
viral RNA [28-30]. Since these proteins are normally
associated with RNA and undergo systematic dissocia-
tion during replication, the tested positively charged
proteins may interfere with this association-dissociation
process or compete for the negative charges on the
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tion pathways.
Conclusion
From the presented data, it can be concluded that esteri-
fication of LF followed by BLG and lastly by ALA
enhances its antiviral activities against H5N1 infected
into MDCK cell lines which is dependent on the concen-
tration of the tested proteins. Consequently, applying this
technique is associated with a protective action on the
cell lines subjected to the viral infection. Further studies
are needed to improve the antiviral activity of both of a-
lactalbumin and to a less extent b-lactoglobulin.
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